The size of the Europe Biochips Market was worth USD 3.49 billion in 2021 and predicted to expand at a CAGR of 21.94% from 2021 to 2026. This value is forecasted to grow USD 9.40 billion by 2026.
Europe is positioned second in leading the dominant shares of the global biochips market in 2019. Rising demand for personalized medicine is significant, propelling the growth of the market. Key player’s presence in this region, which is innovating the technology of drug development with the help of biochips, is another crucial factor favoring the market growth. The governments in different countries in Europe are funding for the development of biochips technology. The European Union is also promoting the use of biochips in research like the NABIS (Nanobiotechnology with self-organizing structures), which is a European Union-funded project. The biochips are also used to trace biological warfare and also used in forensic.
The availability of alternate methods in this region is restricting the market growth to some extent. The cost of biochips is high, and of standardization of biochips are further hindering the growth of the biochips market.
Europe Biochips Market segmented and sub-segmented into the following categories.
Based on Region, Europe is the second-largest market with a global share of 28%. It is projected to grow at one of the highest CAGRs during the forecast period due to various reasons such as easy access to the latest technologies, a large patient pool, and promising government policies.
The United Kingdom biochips market had occupied the majority of the European market in 2019. The Department for Environment Food and Rural Affairs (Defra) is funding the pan viral microarray, which enables the detection of 1132 different viruses from 40 viral families in a single test using biochips. The various institutes in the country are using the biochips for the study of the different biomolecule.
However, the German biochips market is predicted to grow at the fastest growth rate during the forecast period. Germany has a strong key player’s presence, which is significantly favoring market growth. In Germany, they have developed a fingernail-sized DNA chip that can analyze thousands of genes in a tiny sample.
Some of the Prominent Companies leading the Europe Biochips Market Profiled in the Report are Agilent Technologies Inc., Fluidigm Corporation, PerkinElmer Inc., Bio-Rad Laboratories Inc., GE Healthcare, Cepheid Inc., Illumina Inc., and Thermo Fisher Scientific Inc
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 DNA Chips
5.1.2.1 SNP Genotyping
5.1.2.2 Genomics
5.1.2.3 Agricultural Biotechnology
5.1.2.4 Gene Expression
5.1.2.5 Cancer Diagnosis & Treatment
5.1.2.6 Drug Discovery
5.1.2.7 Others
5.1.3 Lab-On-A-Chip
5.1.3.1 Clinical Diagnostics
5.1.3.2 IVD & POC
5.1.3.3 Drug Discovery
5.1.3.4 Genomics
5.1.3.5 Proteomics
5.1.4 Protein Chips
5.1.4.1 Expression Profiling
5.1.4.2 High-Throughput Screening
5.1.4.3 Proteomics
5.1.4.4 Diagnostics
5.1.4.5 Drug Discovery
5.1.5 Other types
5.1.6 Y-o-Y Growth Analysis, By Type
5.1.7 Market Attractiveness Analysis, By Type
5.1.8 Market Share Analysis, By Type
5.2 End User
5.2.1 Introduction
5.2.2 Hospitals and Diagnostics Centers
5.2.3 Biotechnology and Pharmaceutical Companies
5.2.4 Academic & Research Institutes
5.2.5 Y-o-Y Growth Analysis, By End User
5.2.6 Market Attractiveness Analysis, By End User
5.2.7 Market Share Analysis, By End User
5.3 Fabrication Technology
5.3.1 Introduction
5.3.2 Microfluidics
5.3.3 Microarrays
5.3.4 Y-o-Y Growth Analysis, By Fabrication Technology
5.3.5 Market Attractiveness Analysis, By Fabrication Technology
5.3.6 Market Share Analysis, By Fabrication Technology
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By End User
6.1.3.4 By Fabrication Technology
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By End User
6.1.4.4 By Fabrication Technology
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By End User
6.1.5.4 By Fabrication Technology
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Athersys
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 StemCells
8.3 Cryo Cell International
8.4 Geron Corporation
8.5 Mesoblast
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.8 Invitrogen
8.9 Cytori Therapeutics
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
